AnaptysBio Inc. Company Profile
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AnaptysBio at a glance
AnaptysBio Inc. (NASDAQ: ANAB) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. AnaptysBio is led by Mr. Daniel R. Faga. The company's shares have traded publicly since 2017.
At a market capitalization of $1.41 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001370053, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does AnaptysBio do?
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- AnaptysBio Inc.
- Ticker
- NASDAQ: ANAB
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel R. Faga
- Headquarters
- 10770 Wateridge Circle, San Diego, CA, United States
- Phone
- 858 362 6295
- Website
- anaptysbio.com
- IPO year
- 2017
- Market cap
- $1.41B
- SEC CIK
- 0001370053
- Latest annual report
- 10-K/A · Apr 28, 2026
Companies similar to AnaptysBio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs ANAB |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs ANAB |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs ANAB |
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs ANAB |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs ANAB |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs ANAB |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs ANAB |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs ANAB |